{"id":2980,"date":"2018-03-08T14:00:00","date_gmt":"2018-03-08T14:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/information-from-xvivo-perfusions-nomination-committee-2\/"},"modified":"2018-03-08T14:00:00","modified_gmt":"2018-03-08T14:00:00","slug":"information-from-xvivo-perfusions-nomination-committee-2","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/","title":{"rendered":"Information from XVIVO Perfusion\u00b4s Nomination Committee"},"content":{"rendered":"

XVIVO Perfusion AB\u2019s Nomination Committee proposes that the Annual General Meeting to be held on April 27, 2018 re-elects the sitting board members G\u00f6sta Johannesson, Erik von Schenck, Camilla \u00d6berg and Folke Nilsson. Fredrik Mattsson and Semmy R\u00fclf have declined re-election.<\/span><\/p>\n

G\u00f6sta Johannesson is proposed to be elected as the chairman of the board. The Nomination Committee further proposes Yvonne M\u00e5rtensson and Alan Raffensperger as new board members.<\/span><\/p>\n

Yvonne M\u00e5rtensson has a long and solid experience from the Med tech and life science industry, most recently from the role as CEO for CellaVision AB during 1998-2014. Yvonne M\u00e5rtensson also has experience as a board member of life science companies. Yvonne M\u00e5rtensson holds a M.Sc. (Tech.) in Engineering and Management from Link\u00f6ping Institute of Technology.<\/span><\/p>\n

Alan Raffensperger has a long and solid experience from the Med tech and life science industry. Alan is currently CEO for Inceptua SA, and before that the role as COO for SOBI (Swedish Orphan Biovitrum AB) during 2012-2017. Before that, during 2010-2012, Alan Raffensperger was CEO for Benechill Inc. Alan Raffensperger holds a MBA from George Washington University and a B.Sc. in Health Services Management from University of Maryland Baltimore.<\/span><\/p>\n

The Nomination Committee\u2019s other proposals will be published in the notice to the Annual General Meeting.<\/span><\/p>\n

For the 2018 Annual General Meeting, the Nomination Committee members are Henrik Blomquist (Bure Equity), Martin Lewin (Eccenovo AB) and Joachim Spetz (Swedbank Robur). The Nomination Committee has been appointed in accordance with the instruction determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on May 3, 2016.<\/span><\/p>\n

The Annual General Meeting will take place on April 27, 2018 in Gothenburg.<\/span><\/p>\n

XVIVO Perfusion AB (publ)<\/p>\n

Contact person:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0
<\/span>Henrik Blomquist
Nomination Committee Chairman
Tel: +46 8 \u2013 614 00 20
henrik.blomquist@bure.se\u00a0 \u00a0\u00a0<\/p>\n

\n

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication at 3.00 am CET on March 8, 2018.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

XVIVO Perfusion AB\u2019s Nomination Committee proposes that the Annual General Meeting to be held on April 27, 2018 re-elects the…<\/p>\n","protected":false},"template":"","class_list":["post-2980","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nInformation from XVIVO Perfusion\u00b4s Nomination Committee - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Information from XVIVO Perfusion\u00b4s Nomination Committee - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion AB\u2019s Nomination Committee proposes that the Annual General Meeting to be held on April 27, 2018 re-elects the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-from-xvivo-perfusions-nomination-committee-2\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-from-xvivo-perfusions-nomination-committee-2\\\/\",\"name\":\"Information from XVIVO Perfusion\u00b4s Nomination Committee - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-03-08T14:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-from-xvivo-perfusions-nomination-committee-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-from-xvivo-perfusions-nomination-committee-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/information-from-xvivo-perfusions-nomination-committee-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Information from XVIVO Perfusion\u00b4s Nomination Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Information from XVIVO Perfusion\u00b4s Nomination Committee - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/","og_locale":"en_US","og_type":"article","og_title":"Information from XVIVO Perfusion\u00b4s Nomination Committee - XVIVO","og_description":"XVIVO Perfusion AB\u2019s Nomination Committee proposes that the Annual General Meeting to be held on April 27, 2018 re-elects the...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/","name":"Information from XVIVO Perfusion\u00b4s Nomination Committee - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-03-08T14:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/information-from-xvivo-perfusions-nomination-committee-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Information from XVIVO Perfusion\u00b4s Nomination Committee"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}